证券代码：300261 证券简称：雅本化学 公告编号：2025-061 雅本化学股份有限公司 附件：王爱军简历 王爱军，男，中国国籍，1970 年生，硕士，无永久境外居留权。历任上海沪江 德勤会计事务所审计主管，英维斯楼宇系统亚太区财务总监，圣戈班高功能塑料亚 太区财务总监，荟才环球企业咨询（北京）有限公司顾问，伟速达（中国）汽车安 全系统有限公司财务副总，雅本化学股份有限公司董事会秘书。现任雅本化学股份 有限公司财务总监。 截止目前，王爱军先生直接持有公司股份 10,500 股，通过 2023 年员工持股计 划间接持有公司股份 300,000 股。王爱军先生与其他持有公司 5%以上股份的股东、 其他董事、高级管理人员不存在关联关系；不存在《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作（2025 年修订）》第 3.2.3 条所规定 的情形；不存在因涉嫌犯罪被司法机关立案侦查或者涉嫌违法违规被中国证监会立 案调查而尚未有明确结论的情形；未被中国证监会在证券期货市场违法失信信息公 开查询平台公示或者被人民法院纳入失信被执行人名单。其任职资格符合《中华人 民共和国公司法》《深圳证券交易所 ...

证券代码：300261 证券简称：雅本化学 公告编号：2025-059 本议案需提交 2025 年第三次临时股东会审议。 二、审议通过了《关于提请召开 2025 年第三次临时股东会的议案》 经审议，董事会同意于 2025 年 8 月 29 日召开 2025 年第三次临时股东会。详见 中国证监会指定信息披露网站刊登的公告。 雅本化学股份有限公司 第六届董事会第五次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 雅本化学股份有限公司（以下简称"公司"）第六届董事会第五次（临时）会议 于 2025 年 8 月 12 日上午 10:00 以现场结合通讯方式召开，会议通知已于 2025 年 8 月 7 日以邮件方式送达全体董事。本次会议应出席董事 8 名，实际出席会议董事 8 名。会议由公司董事长兼总经理蔡彤先生主持，公司部分高级管理人员列席了会议。 本次会议的召集和召开符合《公司法》和《公司章程》的有关规定。 会议采取记名投票的方式进行表决，经与会的董事充分讨论与审议，会议形成 以下决议： 一、审议通过了《关于增补公司第六届董事会非独立董事的议 ...

Group 1: Chemical and Oil Indices Performance - The chemical index and oil index showed overall positive performance, with the chemical raw materials index rising by 1.66% and the chemical machinery index increasing by 6.08%. However, the chemical pharmaceuticals index fell by 1.30% [1] - In the oil sector, the oil processing index increased by 0.67%, the oil extraction index rose by 2.70%, and the oil trading index went up by 2.18% [1] Group 2: International Oil Prices - International crude oil prices declined, with WTI settling at $63.88 per barrel, down 5.12% from August 1, and Brent settling at $66.597 per barrel, down 4.42% [1] Group 3: Petrochemical Products Price Changes - The top five petrochemical products with price increases included liquid chlorine up by 14.98%, coke up by 4.57%, mancozeb up by 4%, coking coal up by 3.55%, and aniline up by 2.82%. The top five products with price decreases included folic acid down by 6%, acrylic acid down by 5.51%, vitamin D3 down by 5.41%, WTI down by 5.12%, and synthetic ammonia down by 4.90% [1] Group 4: Capital Market Performance of Chemical Companies - The top five chemical companies with the highest stock price increases were Kexin New Energy up by 53.05%, Amway Co. up by 51.60%, Xinhang New Materials up by 45.88%, Zhongxin Fluorine Materials up by 35.66%, and Huaxin New Materials up by 25.99%. The top five companies with the largest declines were Lianhua Technology down by 10.41%, Cangzhou Dahua down by 8.80%, Zaiseng Technology down by 8.63%, Yabeng Chemical down by 7.86%, and Xinchao Energy down by 7.21% [2]

Group 1 - The stock price of Yabao Chemical is reported at 7.97 yuan, down 1.73% from the previous trading day, with a trading volume of 331,452 hands and a transaction amount of 264 million yuan [1] - Yabao Chemical's main business includes the research, production, and sales of pesticides and pharmaceutical intermediates, covering a complete product line in the pesticide sector, including insecticides, fungicides, and herbicides [1] - On August 7, data shows that four funds participated in the research activities of Yabao Chemical, ranking fifth among 16 companies surveyed that day [1]

Group 1: Company Strategy and Development - The company implements a "2+X" strategy focusing on innovative pharmaceuticals and agricultural chemicals CDMO business, establishing stable partnerships with leading global companies [2] - The production system is structured around "six cores + two collaborations," enhancing the R&D process from laboratory to commercial production [2][3] - The company aims to create a comprehensive "R&D-production" lifecycle chain to support high-end innovative products [2] Group 2: Agricultural Chemicals Business - The company has established a production capacity of 2,000 tons/year for chlorantraniliprole intermediates at the Nantong base, serving international agricultural clients for over a decade [3] - The Yancheng base has a production line for custom pesticide projects with an annual capacity of 500 tons, expected to start supplying next year [15] - The Lanzhou base has achieved a production capacity of approximately 500 tons/year for innovative pesticide intermediates, with an additional 1,000 tons/year capacity under installation [15] Group 3: Pharmaceutical Business - The company has over 20 years of experience in the pharmaceutical CDMO sector, providing comprehensive solutions from early drug development to commercial production [12] - The Taicang base has a production capacity of 60 tons/year for the raw material Levetiracetam, while the Malta base supports over 20 types of pharmaceutical raw materials [9] - The Lanzhou pilot base has established a production line for antiviral drug intermediates with an annual capacity of 15 tons [9] Group 4: Strategic Partnerships - The collaboration with Heng Rui Medicine exemplifies the company's "big client strategy," focusing on innovative product commercialization [12] - Plans for 2025 include launching 5-10 cooperative products, with at least 10 products planned for 2026 [11] - The partnership has expanded from small-scale experiments to comprehensive strategic cooperation across multiple therapeutic areas [12] Group 5: Future Outlook and Investment - The company is preparing to invest in new projects and expand production capacity, with over 100 acres of land reserved for future pharmaceutical and agricultural projects [9] - The company anticipates a gradual recovery in agricultural business performance as new projects are implemented [16] - Continuous investment in core technologies and service capabilities is expected to drive high-quality development in the pharmaceutical sector [12]

Summary of Yabon's Conference Call Company Overview - **Company**: Yabon Chemical - **Industry**: Pharmaceutical and Agrochemical CDMO (Contract Development and Manufacturing Organization) Key Points and Arguments 1. **Strategic Partnerships**: Yabon is implementing a major client strategy by establishing strategic partnerships with leading global pharmaceutical and agrochemical companies, focusing on innovative intermediates and derivative products in pharmaceuticals and agrochemicals [2][3][6] 2. **Business Development Strategy**: The company has adopted a "2 Plus X" business development strategy, emphasizing innovative pharmaceutical and agrochemical CDMO services, while deepening relationships with top global enterprises [3][6][19] 3. **Production Capacity Recovery**: Following the 2019 Jiangsu incident, Yabon has expanded its production capacity through new bases in Fushun, Xiangyang, and the newly built Lanzhou base, successfully restoring and enhancing production capabilities [2][4][5] 4. **International Market Expansion**: Yabon is actively expanding its international market presence, with some raw materials already being supplied to global markets including Australia, South Korea, and Indonesia, with plans to further penetrate North and South America [4][5] 5. **Core Production Bases**: The company operates six core bases and two cooperative factories, with significant R&D capabilities located in Shanghai and Huzhou, and a newly established pilot base in Lanzhou [3][7][14] 6. **New Projects and Capacity**: Yabon plans to launch new projects in its Yancheng and Lanzhou bases, expecting to add 2,000 tons of intermediates and raw materials by 2025 to meet market demands [3][19][21][22] 7. **Collaboration with Major Clients**: Yabon has established a strategic collaboration with Heng Rui Pharmaceutical, focusing on innovative drug development, with plans to support multiple clinical projects [12][13][18] 8. **Challenges and Responses**: The company faces challenges from declining prices of major projects and the need for new projects to ramp up. Yabon is addressing these by optimizing production line layouts and ensuring efficient capacity utilization [25][26] Additional Important Content 1. **Technological Advancements**: Yabon is investing in synthetic biology, fluid chemistry, and green carbon reduction, enhancing its capabilities to support its CDMO business [2][3][6] 2. **Regulatory Compliance**: The company has established bases that comply with GMP standards, including its Malta facility, which is crucial for serving export-oriented clients [8][14] 3. **Future Development Plans**: Yabon aims to build a smart Mega factory within three years, enhancing its large-scale manufacturing capabilities and cost efficiency [19] 4. **Flexibility in Production**: The Lanzhou base offers flexible production capabilities, allowing for co-line production to meet diverse customer needs effectively [24] 5. **Market Adaptation**: Yabon is adapting to market changes by focusing on high-end intermediates and raw materials, ensuring a robust supply chain through strategic partnerships [9][18] This summary encapsulates the essential insights from Yabon's conference call, highlighting the company's strategic direction, operational advancements, and market positioning within the pharmaceutical and agrochemical sectors.

8月6日，雅本化学连续4个交易日下跌，区间累计跌幅-7.95%。雅本化学股份有限公司(以下称"公司")创建于2003年7月,2010年2月改制成股份有限公司;2011 年9月在深圳证券交易所创业板上市。 财报显示，南方基金旗下南方中证1000ETF为雅本化学前十大股东，今年一季度减持。今年以来收益率16.35%，同类排名712(总2850)。 | 阶段涨幅 | 季度涨幅 | 今年以来合阶段业绩及同类排名 年度涨幅 | | | | | --- | --- | --- | --- | --- | --- | | | 近1周 | 近1月 | 近3月 | 近6月 | 今年来 | | 阶段涨幅 | 2.15% | 8.88% | 13.47% | 14.69% | 16.35% | | 同类平均� | -0.99% | 5.81% | 12.35% | 13.40% | 11.61% | | 沪深300 | -0.91% | 3.30% | 8.01% | 7.04% | 4.54% | | 股东标的2 | 2.13% | 8.70% | 12.43% | 13.56% | 15.17% | | 同类排名 3 | 36 ...

Core Viewpoint - Yabon's strategic partnership with Heng Rui aims to enhance its innovative pharmaceutical CDMO business competitiveness and expand its business scale, which does not affect its ongoing collaboration with Fumisi [2]. Group 1 - Yabon has signed a strategic cooperation agreement with Heng Rui, focusing on strengthening its CDMO business [2]. - The partnership with Heng Rui is independent of the contract renewal discussions with Fumisi, indicating that both collaborations can coexist without interference [2]. - Although Yabon has not yet completed the renewal agreement with Fumisi, business operations between the two companies are continuing normally, and Yabon is actively supplying products to Fumisi [2].

Group 1: Financial Performance and Projections - The contribution of the agricultural CDMO business to revenue is expected to remain around 50% for both 2023 and 2024 [1] - The company anticipates gradual recovery in the agricultural sector, with improved demand from downstream customers [25] - The company has conducted reasonable impairment provisions for goodwill in 2023 and 2024, with risks of further impairment existing [12] Group 2: Market Trends and Competitive Landscape - The market for chlorantraniliprole intermediates is experiencing intense competition due to a surge in domestic production capacity, impacting raw material prices [2][3] - The company maintains a "big client strategy" to navigate the competitive landscape and enhance cost control for downstream clients [3] Group 3: Strategic Partnerships and Collaborations - The company has established a strategic partnership with Hengrui Medicine, focusing on a full lifecycle collaboration model for product development and commercialization [7][8] - The collaboration with Hengrui is expected to cover major therapeutic areas, including oncology and cardiovascular diseases, with a focus on supply chain needs [8][16] Group 4: Production Capacity and Development Plans - The company is in the process of upgrading its production bases, with a focus on core raw material production and innovative product development [9][14] - The Lanzhou base is expected to see performance improvements as the agricultural sector recovers and customer demand increases [13] Group 5: Risk Management and Inventory Control - The company employs dynamic inventory management based on historical sales data and market trends to ensure stable supply for major clients [11] - The company is closely monitoring international trade policies and their impact on export operations, maintaining flexibility in supply chain management [14]

证券之星消息，8月5日农化制品板块较上一交易日上涨0.34%，丰山集团领涨。当日上证指数报收于 3617.6，上涨0.96%。深证成指报收于11106.96，上涨0.59%。农化制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603810 | 丰山集团 | 17.27 | 3.85% | 3.14万 | 5362.57万 | | 002734 | 利民股份 | 21.88 | 2.87% | 59.84万 | 12.96ZZI | | 000422 | 湖北宣化 | 13.54 | 2.19% | 27.13万 | 3.63亿 | | 000902 | 新洋丰 | 14.40 | 1.91% | 10.80万 | 1.55亿 | | 300387 | 富邦科技 | 9.54 | 1.81% | 9.53万 | 9061.10万 | | 002545 | 东方铁塔 | 9.86 | 1.75% | 11.65万 | 1.15亿 | | 002470 | 金正大 | 1.7 ...